PHC
28.4.2022 12:07:18 CEST | Business Wire | Press release
PHC Holdings Corporation (hereafter PHC Group) (TOKYO:6523) today announced the appointment of Shoji Miyazaki as the company’s Chief Executive Officer. He succeeds John Marotta, who has stepped down as the company’s CEO and Representative Director and also from the Board of Directors effective April 28, 2022. Shoji Miyazaki remains a Representative Director on the company’s Board of Directors.
Shoji Miyazaki was previously PHC Group's Chief Operating Officer and former President of PHC Corporation and brings more than 30 years of experience at PHC Group and Panasonic. He joined Matsushita Kotobuki Electronics Co., Ltd. a predecessor of PHC Corporation in 1990, upon graduation. In 2001 he moved to Panasonic’s healthcare medical business unit, focusing on medical diagnostics, where he continued in numerous roles before being appointed Executive Vice President and COO of PHC Holdings Corporation in 2020. At the same time he also held Board positions at PHC Corporation and LSI Medience Corporation.
“I look forward to focusing on efficiency and integration, building on the work our team has delivered integrating our teams and portfolio since the acquisitions of Epredia and LSI Medience in 2019. Delivering value for patients, clinicians, business partners and shareholders remains PHC Group’s top priority,” commented Shoji Miyazaki.
In addition, effective July 1, 2022, Board Member Koichiro Sato will join PHC Group as Chief Operating Officer. On the same date, subject to approval of the proposal for election of directors at the General Meeting of Shareholders, he will become a Representative Director. His main responsibility will be overseeing company operations outside of Japan, where half PHC Group’s business and employees are located, including Ascensia, Epredia, and PHCbi NA and EU. Sato joins PHC Group from his current role as Chief Executive Officer in the Hong Kong Branch of MBK Healthcare Management Pte. Ltd. and he brings nearly 25 years of experience to PHC Group from his international career within Mitsui & Co. related companies. He entered the healthcare field in 2016 as a general manager in the Mitsui healthcare business division.
“We are pleased to welcome Shoji Miyazaki as PHC Group’s new CEO. He has a strong track record of leading global teams across diagnostics, life sciences, and diabetes, and is particularly well suited to driving the next leg of innovation from PHC Group. We continue to be committed to creating healthcare solutions that improve lives and strengthen our communities,” said Kyoko Deguchi, External Director.
“PHC Group looks forward to advancing our medium- and long-term plans to deliver global growth, innovation, efficiency, and performance, and to continue contributing to a healthier society. We thank John for his concentrated efforts on bringing the company to the IPO, streamlining and integrating the organization, and bringing consistency to PHC Group’s management systems and structures. We wish him all the best,” continued Ivan Tornos, External Director.
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TOKYO:6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia, and LSI Medience Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2020 were JPY 306 billion with global distribution of products and services in more than 125 countries.
www.phchd.com/global
www.phchd.com/global/news/2022/0428
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005524/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom